Company profile

Head office: Creative Lab in Kobe (CLIK)

Research Lab
Company name Bacchus Bio Innovation Co., Ltd.
Address 6-3-7 Minatojima Minami-machi, Chuo-ku, Kobe-city, Hyogo
Establishment March 18, 2020
Capital 4.1 Billion yen (as of April 2024)
Business content Integrated BioFoundry
  • DBTL: BioFoundry (ultrahigh-speed microbial breeding)
  • DBTL: Elementary technology utilization
  • Scale-up process development
  • In-house product development
  • Intestinal microbiome model
Number of employees 64 (as of April 1, 2024)
Board members
Chairman George Hara Chairman of DEFTA Partners Group
President, Founder, and
Representative Director
Akihiko Kondo Professor and Vice President, Kobe University
Director Makoto Hattori
Director Mikio Tanji DEFTA Partners Group
External director Kunio Yamada Chairman and Representative Director,
Rohto Pharmaceutical Co.
External director Norio Yamakawa Executive Officer, Taiyo Oil Co.
Auditor Matsuda Hitoshi

Asia’s pioneer Integrated BioFoundry®

Expanding bio-manufacturing to contribute towards solving global issues

“Bacchus” is the “God of wine” who appears in Roman mythology for bringing rich culture and happiness to people through biotechnology (brewing technology). Our company’s name reflects our desire to lead the world’s bio-innovation.

  • IT × BIOFusion of IT and Biotechnology

    We develop and utilize the “Digital x Bio” platform for the production of value-added substances from microorganisms. We aim to become a flexible BioFoundry for easy B2B collaborations.

  • TrustBecoming a trusted name

    We aim to achieve carbon neutrality by 2050 through a recycling-oriented bio-manufacturing society. Jointly developing innovative solutions with academia, we leverage the expertise of our skilled professionals from various fields in national projects with the Ministry of Economy, Trade, and Industry and NEDO.

  • InheritancePassing down our technology and knowledge to the future

    We are accepting human resources from various fields, especially young researchers who will lead the future and achieve sustainable innovation through collaboration with industry and academia.

  • GlobalTowards leading the world’s biotech industry

    We aim to work with partners to develop multiple pipeline candidates while also creating our own products. Our goal is to become a world leader in biotechnology.

PhilosophyWe aim to contribute to a society where everyone can be happy.

Our company contributes from a medium- to long-term perspective for everyone involved, including clients, employees, local communities, and the earth, as well as all of our colleagues who lead our company to growth. Our philosophy is that as a result, our corporate value (not market capitalization, but the total added value for everyone involved with our company) will increase.

MissionWe will create a new industry in the “Digital x Bio" era.

Based on the philosophy of “realizing a society where people can stay healthy until just before reaching the end of their natural lives,'' our company develops fundamental technologies that are the result of cutting-edge research and development centered on synthetic biology at Kobe University. We aim to transfer the knowledge and realize Asia's first Integrated BioFoundry.By collaborating with industry and research institutes mainly in the Kansai region, we will create new industries for the "digital x bio" era in Japan, creating jobs, enriching people's lives, and enabling them to live long, healthy lives. Our mission is to contribute to the creation of a healthy and happy society.

Business policyAiming to build a unique and advanced industrial infrastructure.

By fusing digital technology and biotechnology, we aim to build advanced industrial infrastructure that cannot be imitated by other companies. We also provide services to a wide range of industries from Japan and the Asian region. Our business policy is to create new industries from the Kobe/Osaka Greater Bay Area by promoting the bioeconomy through the development of our company.

Value proposition

  • Competitive Pricing

    We offer reduced hurdles and ease of approach from the customer’s perspective while searching for high-value and high-risk candidate compounds.

  • Ability for a variety of target compounds

    Our technology is compatible with a variety of compounds, proteins, RNA, cells, and so on.

  • Ability to work with diverse host organisms

    Our platform is compatible with Escherichia coli, lactic acid bacteria, Bacillus subtilis, actinomycetes, Saccharomyces cerevisiae, Pichia yeast, filamentous fungi, microalgae, and more.

  • Advanced Breeding Technology

    We provide advanced breeding technology by combining synthetic biology with non-genetically modified organisms.

  • Overseas expansion

    We plan to expand our business not only in Japan but in Asia, with a special focus on Hong Kong and Singapore.

  • Complete integration

    Our platform offers a comprehensive solution that automates the biomanufacturing process, incorporating the necessary technology, knowledge, and equipment.